The Model Gap
The translation of genomic discovery into practical diagnostic, prognostic, theranostic and drug discovery tools all require the development of accurate laboratory-based models that recapitulate the various genetic events identified as significant in human cancer onset and progression. Such models can be widely deployed to support the rapid development of the personalized medicine paradigm.
 |
| + Zoom image |
GENESIS™ confers the ability to rapidly introduce subtle, yet highly significant ‘gain-of-function’ disease mutations (common in many forms of cancer), as well as loss-of-function alterations, into any endogenous gene loci of human cells; thus accurately and definitively modeling real patient genotypes.
By enabling the key genetic variations that define a patient genotype to be routinely engineered in a human cell, the model gap is bridged and a means to the implementation of improved drug discovery paradigms that will better target the genetic make-up of individual cancer patients is at hand.
More information
